Candesartan Cilexetil Tablet
Product Images NDC 62332-342

This is a medication package of Candesartan Cilexetil tablets containing 16 mg of the active ingredient. The recommended adult dosage is provided in the package insert, and the tablets should be stored at controlled room temperature. The tablets are manufactured by Alembic Pharmaceuticals in Gujarat, India, and distributed by Alembic Pharmaceuticals in Bedminster, NJ, USA. The package contains 30 tablets and has a unique NDC code assigned to it. Additionally, it includes a manufacturing code and an expiration date.*

Each uncoated tablet contains 4mg of Candesartan Cilexetil, USP. The usual adult dosage is mentioned on the package insert. The tablets should be stored at a temperature of 25°C (17°F) with excursions permitted up to 15° to 30°C (59° to 86°F) as per USP Controlled Room Temperature guidelines. These tablets are manufactured in Gujarat, India, by Alembic Pharmaceuticals Limited (Formulation Division) and are sold in the USA by Alembic Pharmaceuticals, Inc. Each package contains 30 tablets that are only available with a prescription. The product code for these tablets is NDC 62332-341-30, and they come with a GTIN number of 00362332341306. The remaining text on the packaging is mostly manufacturing-related information such as the production and expiry date, batch number, etc.*

This is a medication called Candesartan Cilexetil with a strength of 8mg that comes in tablet form. The usual adult dosage is listed in the package insert and the medication should be stored at a controlled room temperature between 15°C to 30°C (59°F to 86°F). The manufacturer is Alembic Pharmaceuticals Limited located in Gujarat, India and the medication is manufactured for Alembic Pharmaceuticals, Inc. located in Bedminster, NJ, USA. The product comes in a package of 30 tablets and is available only by prescription. There are additional codes and information in a coding area that is not intended to be printed.*

This text provides information about a clinical trial including patient demographics and medical history. The data includes age, sex, race, NYHA classification, LVEF, medical history, and medication use for all patients (n=4576). The trial consists of two treatment groups: candesartan and placebo, with respective patient counts and outcomes provided. A hazard ratio is also reported. This text may be useful for researchers or healthcare professionals seeking to understand the baseline characteristics and outcomes of patients in this clinical trial.*